We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
Read MoreHide Full Article
Key Takeaways
Black Diamond is advancing silevertinib for EGFR-mutant NSCLC and glioblastoma.
BDTX outlicensed BDTX-4933 to Servier for $70M, streamlining focus on silevertinib.
Cash reserves of $142.8M are expected to fund operations into Q4 2027.
Black Diamond Therapeutics, Inc. ((BDTX - Free Report) ) is developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s lead pipeline candidate is silevertinib.
Silevertinib is a brain penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
The company recently completed enrollment in the mid-stage study of silevertinib in frontline NSCLC patients with non-classical EGFR mutations.
Black Diamond ended the second quarter of 2025 with approximately $142.8 million in cash and cash equivalents. The company believes that this cash balance is sufficient to fund its anticipated operating expenses and capital expenditure requirements into the fourth quarter of 2027.
Operating expenses in the second quarter plunged 39% due to a decline in R&D and G&A expenses. The decrease in R&D expenses was primarily due to workforce efficiencies and the outlicensing of BDTX-4933, which allowed for an increased focus on the development of silevertinib.
BDTX entered into a global licensing agreement with Servier Pharmaceuticals in March 2025 for its second clinical-stage asset, BDTX-4933, a potential best-in-class targeted therapy for RAF/RAS-mutant solid tumors. The company received an upfront payment of $70.0 million.
Following the outlicensing of its other pipeline candidate, BDTX-4933, to Servier Pharmaceuticals, BDTX is solely focused on the development of silevertinib.
G&A expenses declined primarily due to the restructuring announced in October 2024.
Black Diamond Therapeutics is currently looking for strategic partners to advance further development of silevertinib for NSCLC and GBM.
Competition for BDTX’s Oncology Drug
The NSCLC space is dominated by pharma bigwigs. In August 2024, Johnson & Johnson ((JNJ - Free Report) ) obtained FDA approval of Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EFGR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
Following the approval, JNJ’s Rybrevant plus Lazcluze became the first and only multitargeted, chemotherapy-free combination regimen with demonstrated superiority versus AstraZeneca’s ((AZN - Free Report) ) Tagrisso (osimertinib), approved for the first-line treatment of patients with EGFR-mutated NSCLC.
Earlier, in March 2024, JNJ obtained FDA approval for Rybrevant in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
In patients with EGFR non-classical mutations, silevertinib will compete with AZN’s Tagrisso, which is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases.
AZN is also evaluating Tagrisso in the early-stage adjuvant lung cancer in the resectable setting in a phase III study.
BDTX Price Performance, Valuation and Estimates
Shares of BDTX have surged 57.5% year to date compared with the industry’s growth of 5.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, BDTX is inexpensive. Going by the price/book ratio, BDTX’s shares currently trade at 1.45x book value, higher than its mean of 1.31x but lower than the biotech industry’s 3.16x.
Image Source: Zacks Investment Research
The bottom-line estimate for 2025 has moved north to 33 cents in the past 60 days while that for 2026 has improved 10 cents to a loss of 82 cents per share.
Image: Bigstock
Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?
Key Takeaways
Black Diamond Therapeutics, Inc. ((BDTX - Free Report) ) is developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company’s lead pipeline candidate is silevertinib.
Silevertinib is a brain penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
The company recently completed enrollment in the mid-stage study of silevertinib in frontline NSCLC patients with non-classical EGFR mutations.
Black Diamond ended the second quarter of 2025 with approximately $142.8 million in cash and cash equivalents. The company believes that this cash balance is sufficient to fund its anticipated operating expenses and capital expenditure requirements into the fourth quarter of 2027.
Operating expenses in the second quarter plunged 39% due to a decline in R&D and G&A expenses. The decrease in R&D expenses was primarily due to workforce efficiencies and the outlicensing of BDTX-4933, which allowed for an increased focus on the development of silevertinib.
BDTX entered into a global licensing agreement with Servier Pharmaceuticals in March 2025 for its second clinical-stage asset, BDTX-4933, a potential best-in-class targeted therapy for RAF/RAS-mutant solid tumors. The company received an upfront payment of $70.0 million.
Following the outlicensing of its other pipeline candidate, BDTX-4933, to Servier Pharmaceuticals, BDTX is solely focused on the development of silevertinib.
G&A expenses declined primarily due to the restructuring announced in October 2024.
Black Diamond Therapeutics is currently looking for strategic partners to advance further development of silevertinib for NSCLC and GBM.
Competition for BDTX’s Oncology Drug
The NSCLC space is dominated by pharma bigwigs. In August 2024, Johnson & Johnson ((JNJ - Free Report) ) obtained FDA approval of Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EFGR exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
Following the approval, JNJ’s Rybrevant plus Lazcluze became the first and only multitargeted, chemotherapy-free combination regimen with demonstrated superiority versus AstraZeneca’s ((AZN - Free Report) ) Tagrisso (osimertinib), approved for the first-line treatment of patients with EGFR-mutated NSCLC.
Earlier, in March 2024, JNJ obtained FDA approval for Rybrevant in combination with chemotherapy (carboplatin-pemetrexed) for the first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
In patients with EGFR non-classical mutations, silevertinib will compete with AZN’s Tagrisso, which is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against central nervous system metastases.
AZN is also evaluating Tagrisso in the early-stage adjuvant lung cancer in the resectable setting in a phase III study.
BDTX Price Performance, Valuation and Estimates
Shares of BDTX have surged 57.5% year to date compared with the industry’s growth of 5.6%.
Image Source: Zacks Investment Research
From a valuation standpoint, BDTX is inexpensive. Going by the price/book ratio, BDTX’s shares currently trade at 1.45x book value, higher than its mean of 1.31x but lower than the biotech industry’s 3.16x.
Image Source: Zacks Investment Research
The bottom-line estimate for 2025 has moved north to 33 cents in the past 60 days while that for 2026 has improved 10 cents to a loss of 82 cents per share.
Image Source: Zacks Investment Research
BDTX currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.